We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > INmune Bio

News List

INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune, Successfully Produced Memory-Like NK Cells firstwordpharma
August 26, 2021
INmune Bio, Inc. (NASDAQ: INMB) announced today that the first patient who received INKmune™ as a potential treatment for high-risk myelodysplastic syndrome (MDS) has successfully shown the NK activation and functional differentiation predicted.
First COVID-19 patient dosed in Phase II trial of Quellor europeanpharmaceuticalreview
November 17, 2020
The first patient has been dosed with Quellor in a Phase II clinical trial, evaluating the drug for the treatment of pulmonary complications from COVID-19.
INmune Bio gets US FDA nod for Phase II trial of Quellor, a sTNF inhibitor for COVID-19 treatment expresspharma
September 02, 2020
Trial to evaluate the efficacy of Quellor to blunt the cytokine storm and decrease the catastrophic complications of COVID-19 infection.